中
HOME
About Us
Overview
Management Team
History
Technology
Partnership
Fields
Formats
Partners
Product & Service
Product
Service
Newsroom
Contact Us
Contact Us
2024-04-10
XlifeSc Showcases New Cancer Immunotherapy Strategy at 2024 AACR Annual Meeting
2023-08-09
Major Publication: China's First TCR-T Product Phase I Clinical Research Results
2022-07-10
China’s First TCR-T Cell Therapy Asset Officially Commences Phase II Clinical Trials
2022-06-10
Tumor Response Rate (ORR) Reaches 41.7%! XLifeSc TCR-T Cell Therapy's Chinese Clinical Data Presented at ASCO 2022
2020-10-13
Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan
More
